Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Arnedos on the POP Randomized Trial for Early Breast Cancer

Monica Arnedos, MD
Published: Monday, May 16, 2016



Monica Arnedos, MD, assistant professor, Department of Medical Oncology, Institut de Cancérologie Gustave Roussy, discusses the Preoperative Palbociclib (POP) Randomized Trial for early-stage breast cancer.

Arnedos and researchers sought to determine whether short-term palbociclib (Ibrance) in the neoadjuvant setting would lead to decreased proliferation and early biomarker changes in patients with early-stage breast cancer. Because palbociclib is normally given in combination with other agents, it is difficult to assess its efficacy as a single agent, Arnedos explains.

In this study, palbociclib was administered for 14 days. Results showed that short-term palbociclib had a significant impact on proliferation in patients who were hormone receptor-positive/HER2-negative. Though a normal treatment cycle is 1 month, researchers were able to determine which patients would have any response to palbociclib at the end of the 2-week cycle.




Monica Arnedos, MD, assistant professor, Department of Medical Oncology, Institut de Cancérologie Gustave Roussy, discusses the Preoperative Palbociclib (POP) Randomized Trial for early-stage breast cancer.

Arnedos and researchers sought to determine whether short-term palbociclib (Ibrance) in the neoadjuvant setting would lead to decreased proliferation and early biomarker changes in patients with early-stage breast cancer. Because palbociclib is normally given in combination with other agents, it is difficult to assess its efficacy as a single agent, Arnedos explains.

In this study, palbociclib was administered for 14 days. Results showed that short-term palbociclib had a significant impact on proliferation in patients who were hormone receptor-positive/HER2-negative. Though a normal treatment cycle is 1 month, researchers were able to determine which patients would have any response to palbociclib at the end of the 2-week cycle.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Miami Breast Cancer Conference®: Attendee Tumor Board OnlineNov 30, 20181.5
Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™Dec 31, 20181.5
Publication Bottom Border
Border Publication
x